Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-10-10, Stock:LLY, The news for the past five days is as follows:
2019-10-03: NEWS1: Biotech Stock On The Radar: FDA Verdict Ahead For Pfenex's Osteoporosis Biosimilar.NEWS2: Top Research Reports for Bank of America, Home Depot & Philip Morris.NEWS3: Pres. Trump to expand private Medicare Advantage program.NEWS4: Why Lilly (LLY) Could Beat Earnings Estimates Again.NEWS5: Novartis Reports Additional Data on Spondylitis Drug Cosentyx.NEWS6: Eli Lilly to voluntarily delist from Euronext Paris exchange.NEWS7: Here's Why You Should Add Thermo Fisher to Your Portfolio.NEWS8: Lilly Announces Voluntary Delisting from Euronext Paris.NEWS9: New Head-to-Head Data Show Taltz® (ixekizumab) Superiority versus TREMFYA® (guselkumab) in People with Moderate to Severe Plaque Psoriasis.
2019-10-04: NEWS1: The Zacks Analyst Blog Highlights: Bank of America, Home Depot, Philip Morris, NextEra and Eli Lilly.
2019-10-07: NEWS1: 52-Week Company Lows.NEWS2: Thermo Fisher Closes API Site Buyout, Fortifies Pharma Unit.NEWS3: Novo Nordisk Focuses on Pipeline Development Amid Competition.NEWS4: Lilly's CYRAMZA® (ramucirumab) Phase 3 Data in First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published in The Lancet Oncology.NEWS5: FDA approves Pfenex's osteoporosis therapy.
2019-10-08: NEWS1: UPDATE 2-Humira, Rituxan top list of U.S. drugs with biggest price increases -report.NEWS2: Can We See Significant Institutional Ownership On The Eli Lilly and Company (NYSE:LLY) Share Register?.NEWS3: REFILE-UPDATE 1-Humira, Rituxan top list of U.S. drugs with biggest price increases -report.NEWS4: REFILE-Humira, Rituxan top list of U.S. costliest drug price increases -report.NEWS5: Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress.
2019-10-09: NEWS1: Verzenio™ (abemaciclib) Significantly Extends Life by a Median of 9.4 Months for Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 Study.NEWS2: Gilead (GILD) Files NDA for RA Candidate Filgotinib in Japan.

Answer: Decrease